Improving genetic testing for breast and ovarian cancer in diverse women
Official title: Electronic health record (EHR)-based implementation strategies and decision support for hereditary breast and ovarian cancer (HBOC) genetic testing among multiethnic women (ELISABETH)
Funded at Columbia University Health Sciences · NIH-11035750 · Data updated 2026-11-12
This study is all about helping women, especially those from different backgrounds, get better access to genetic testing for breast and ovarian cancer, so they can understand their risk and make informed choices about their health.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | March 1, 2025 |
| Project end | February 28, 2027 |
| Funding year | 2025 |
| Award (this year) | $686,993 |
| NIH project number | 1UG3CA297490-01 |
| Project ID | NIH-11035750 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include women, particularly those from multiethnic backgrounds, who may be at risk for hereditary breast and ovarian cancer due to family history or genetic factors.
✕Less likely to help
Patients who do not have a family history of breast or ovarian cancer or those who are not interested in genetic testing may not benefit from this research.
What this research studies
This research focuses on enhancing the use of genetic testing for hereditary breast and ovarian cancer (HBOC) among women, particularly those from diverse backgrounds. It aims to identify women with genetic variants that increase their cancer risk, enabling better management strategies like increased screening and preventive surgeries. The project utilizes electronic health records to implement decision support tools for both patients and primary care providers, addressing barriers to testing and improving access to genetic counseling. By integrating family history screening into routine care, the research seeks to increase the rates of genetic testing among underrepresented populations.
Why it matters
Potential benefit: If successful, this research could significantly increase the identification of women at high risk for breast and ovarian cancer, leading to earlier interventions and improved health outcomes.
How similar studies have gone: Previous research has shown success in increasing genetic testing rates through similar implementation strategies and decision support tools.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Crew, Katherine D — Columbia University Health Sciences
- Study coordinator: Crew, Katherine D
Related research
Other NIH-funded projects on the same topics.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Integrated framework to validate and quantify proteoforms in patient-derived ovarian cancer cells
A collaboration will combine advanced top-down proteomics with a new computational method to precisely identify and measure intact proteoforms in tiny samples from ovarian cancer cells.
-
Overcoming platinum resistance in ovarian cancer: finding biomarkers and new targets
Researchers are looking for new biomarkers and targets to help prevent or overcome platinum resistance in high‑risk ovarian cancer so patients have better chances at long-term control.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.